BV4 supports EIT Health for its 2022 Startup Amplifier Program
BV4 acted as an independent advisory for EIT Health's Startup Amplifier 2022 Program where our analysts have performed multiple due diligence and valuation of the program's incoming startup applications. Various startup cases from Seed to Series A in the field of MedTech, HealthTech and BioTech were analyzed and valuated. The experts applied BV4’s proprietary valuation methodology for early-stage companies and evaluated the startup cases on a holistic approach covering the commercial, financial aspect as well as the legal aspect through a legal self-assessment specifically created for the purpose of an efficient due diligence.
Thanks to the expertise and the engagement of BV4, the most promising startup cases could be identified and recommended to EIT Health. The European entity will pursue in granting funding according to the calculated valuation by BV4. The mandate is part of an ongoing relationship between the two entities since 2019.